Literature DB >> 7533455

Characterization and localization of nitric oxide synthase in the human prostate.

A L Burnett1, M P Maguire, S L Chamness, D D Ricker, M Takeda, H Lepor, T S Chang.   

Abstract

OBJECTIVES: To characterize nitric oxide synthase (NOS), which catalyzes nitric oxide (NO) production, in the human prostate using biochemical and immunohistochemical techniques.
METHODS: NOS catalytic assay and NOS immunohistochemistry were performed on histologically verified nonmalignant prostate tissue obtained from the peripheral and transition zones of seven radical prostatectomy specimens.
RESULTS: Biochemical analysis revealed NOS activity in the human prostate, with a greater amount in the peripheral zone than in the transition zone (P < 0.01). In both prostate zones, NOS was immunohistochemically localized to nerve fibers and ganglia coursing throughout the smooth musculature of the stroma and to subepithelial nerve plexuses. NOS immunoreactivity was also localized to glandular epithelium.
CONCLUSIONS: The presence, activity, and distribution of NOS were described in two regions of the human prostate. The present evidence implicates NO in the automatic innervation and physiology of the human prostate. It is proposed that NO may modulate smooth muscle tone and secretory functions in the human prostate, although functional studies are needed to support these hypotheses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533455     DOI: 10.1016/S0090-4295(99)80012-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  23 in total

1.  The comparison of GLUT-4 and nNOS expression in diabetic and non-diabetic patients with BPH/LUTS.

Authors:  Alper Otunctemur; Huseyin Besiroglu; Murat Dursun; Levent Ozcan; Emre Can Polat; Adnan Somay; Nurver Ozbay; Kutan Ozer; Emin Ozbek
Journal:  Int Urol Nephrol       Date:  2015-04-03       Impact factor: 2.370

2.  The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2006

3.  [Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function. An immunohistochemical and functional study].

Authors:  S Uckert; K Sigl; E S Waldkirch; P Sandner; E Ulbrich; M Oelke; C G Stief; M A Kuczyk
Journal:  Urologe A       Date:  2009-07       Impact factor: 0.639

Review 4.  Stimulators and activators of soluble guanylate cyclase for urogenital disorders.

Authors:  Fabiola Z Mónica; Edson Antunes
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

5.  Genetic variants within endothelial nitric oxide synthase gene and prostate cancer: a meta-analysis.

Authors:  Zorana Z Nikolić; Dušanka Lj Savić Pavićević; Stanka P Romac; Goran N Brajušković
Journal:  Clin Transl Sci       Date:  2014-08-27       Impact factor: 4.689

Review 6.  Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract--is there a basis for pharmacological targeting of cGMP?

Authors:  Petter Hedlund
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

7.  Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2004

8.  Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia.

Authors:  T Klotz; M J Mathers; W Bloch; W Nayal; U Engelmann
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

9.  Impact of preoperative haemoglobin concentrations on the efficiency of KTP-laser vaporization of the prostate.

Authors:  Stephan Buse; Christian Gilfrich; Gencay Hatiboglu; Johannes Huber; Jens Bedke; Jesco Pfitzenmaier; Axel Haferkamp; Markus Hohenfellner
Journal:  World J Urol       Date:  2009-01-15       Impact factor: 4.226

Review 10.  The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms.

Authors:  George T Kedia; Stefan Uckert; Udo Jonas; Markus A Kuczyk; Martin Burchardt
Journal:  World J Urol       Date:  2008-07-08       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.